Literature DB >> 23463508

Cysteine-rich domain 1 of CD40 mediates receptor self-assembly.

Cristian R Smulski1, Julien Beyrath, Marion Decossas, Neila Chekkat, Philippe Wolff, Karine Estieu-Gionnet, Gilles Guichard, Daniel Speiser, Pascal Schneider, Sylvie Fournel.   

Abstract

The activation of CD40 on B cells, macrophages, and dendritic cells by its ligand CD154 (CD40L) is essential for the development of humoral and cellular immune responses. CD40L and other TNF superfamily ligands are noncovalent homotrimers, but the form under which CD40 exists in the absence of ligand remains to be elucidated. Here, we show that both cell surface-expressed and soluble CD40 self-assemble, most probably as noncovalent dimers. The cysteine-rich domain 1 (CRD1) of CD40 participated to dimerization and was also required for efficient receptor expression. Modelization of a CD40 dimer allowed the identification of lysine 29 in CRD1, whose mutation decreased CD40 self-interaction without affecting expression or response to ligand. When expressed alone, recombinant CD40-CRD1 bound CD40 with a K(D) of 0.6 μM. This molecule triggered expression of maturation markers on human dendritic cells and potentiated CD40L activity. These results suggest that CD40 self-assembly modulates signaling, possibly by maintaining the receptor in a quiescent state.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23463508      PMCID: PMC3624471          DOI: 10.1074/jbc.M112.427583

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.

Authors:  S S Pullen; M E Labadia; R H Ingraham; S M McWhirter; D S Everdeen; T Alber; J J Crute; M R Kehry
Journal:  Biochemistry       Date:  1999-08-03       Impact factor: 3.162

2.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling.

Authors:  F K Chan; H J Chun; L Zheng; R M Siegel; K L Bui; M J Lenardo
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

3.  Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations.

Authors:  R M Siegel; J K Frederiksen; D A Zacharias; F K Chan; M Johnson; D Lynch; R Y Tsien; M J Lenardo
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

4.  Structures of the extracellular domain of the type I tumor necrosis factor receptor.

Authors:  J H Naismith; T Q Devine; T Kohno; S R Sprang
Journal:  Structure       Date:  1996-11-15       Impact factor: 5.006

5.  Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.

Authors:  Hyun-Jung An; Young Jin Kim; Dong Hyun Song; Beom Suk Park; Ho Min Kim; Ju Dong Lee; Sang-Gi Paik; Jie-Oh Lee; Hayyoung Lee
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

6.  CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization.

Authors:  S S Pullen; H G Miller; D S Everdeen; T T Dang; J J Crute; M R Kehry
Journal:  Biochemistry       Date:  1998-08-25       Impact factor: 3.162

Review 7.  CD40-CD40 ligand.

Authors:  C van Kooten; J Banchereau
Journal:  J Leukoc Biol       Date:  2000-01       Impact factor: 4.962

8.  A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells.

Authors:  Carina Banning; Jörg Votteler; Dirk Hoffmann; Herwig Koppensteiner; Martin Warmer; Rudolph Reimer; Frank Kirchhoff; Ulrich Schubert; Joachim Hauber; Michael Schindler
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

9.  Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.

Authors:  Yulian Wu; Bing Han; Hongwei Sheng; Min Lin; Paul A Moore; Jun Zhang; Jiangping Wu
Journal:  Int J Cancer       Date:  2003-07-10       Impact factor: 7.396

10.  Polymyxin B as inhibitor of LPS contamination of Schistosoma mansoni recombinant proteins in human cytokine analysis.

Authors:  Luciana S Cardoso; Maria Ilma Araujo; Alfredo M Góes; Lucila G Pacífico; Ricardo R Oliveira; Sergio C Oliveira
Journal:  Microb Cell Fact       Date:  2007-01-03       Impact factor: 5.328

View more
  16 in total

Review 1.  Regulation of NF-κB by TNF family cytokines.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Semin Immunol       Date:  2014-06-21       Impact factor: 11.130

2.  Insights into ligand binding by a viral tumor necrosis factor (TNF) decoy receptor yield a selective soluble human type 2 TNF receptor.

Authors:  Sergio M Pontejo; Carolina Sanchez; Begoña Ruiz-Argüello; Antonio Alcami
Journal:  J Biol Chem       Date:  2019-02-05       Impact factor: 5.157

Review 3.  Influence of immunoglobulin isotype on therapeutic antibody function.

Authors:  Stephen A Beers; Martin J Glennie; Ann L White
Journal:  Blood       Date:  2016-01-13       Impact factor: 22.113

4.  Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.

Authors:  Ann L White; H T Claude Chan; Ruth R French; Jane Willoughby; C Ian Mockridge; Ali Roghanian; Christine A Penfold; Steven G Booth; Ali Dodhy; Marta E Polak; Elizabeth A Potter; Michael R Ardern-Jones; J Sjef Verbeek; Peter W M Johnson; Aymen Al-Shamkhani; Mark S Cragg; Stephen A Beers; Martin J Glennie
Journal:  Cancer Cell       Date:  2014-12-11       Impact factor: 31.743

5.  Secreted APE1/Ref-1 inhibits TNF-α-stimulated endothelial inflammation via thiol-disulfide exchange in TNF receptor.

Authors:  Myoung Soo Park; Sunga Choi; Yu Ran Lee; Hee Kyoung Joo; Gun Kang; Cuk-Seong Kim; Soo Jin Kim; Sang Do Lee; Byeong Hwa Jeon
Journal:  Sci Rep       Date:  2016-03-11       Impact factor: 4.379

6.  Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling.

Authors:  Cristian R Smulski; Marion Decossas; Neila Chekkat; Julien Beyrath; Laure Willen; Gilles Guichard; Raquel Lorenzetti; Marta Rizzi; Hermann Eibel; Pascal Schneider; Sylvie Fournel
Journal:  Cell Death Dis       Date:  2017-02-09       Impact factor: 8.469

7.  Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.

Authors:  Julien Beyrath; Neila Chekkat; Cristian R Smulski; Caterina M Lombardo; Marie-Charlotte Lechner; Cendrine Seguin; Marion Decossas; Maria Vittoria Spanedda; Benoît Frisch; Gilles Guichard; Sylvie Fournel
Journal:  Oncotarget       Date:  2016-10-04

8.  Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.

Authors:  Xiaojie Yu; H T Claude Chan; Christian M Orr; Osman Dadas; Steven G Booth; Lekh N Dahal; Christine A Penfold; Lyn O'Brien; C Ian Mockridge; Ruth R French; Patrick Duriez; Leon R Douglas; Arwen R Pearson; Mark S Cragg; Ivo Tews; Martin J Glennie; Ann L White
Journal:  Cancer Cell       Date:  2018-03-22       Impact factor: 31.743

Review 9.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

10.  TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.

Authors:  Xiaojie Yu; Sonya James; James H Felce; Blanka Kellermayer; David A Johnston; H T Claude Chan; Christine A Penfold; Jinny Kim; Tatyana Inzhelevskaya; C Ian Mockridge; Yasunori Watanabe; Max Crispin; Ruth R French; Patrick J Duriez; Leon R Douglas; Martin J Glennie; Mark S Cragg
Journal:  Commun Biol       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.